Clopidogrel after MI less effective in diabetes patients

September 5, 2012
Clopidogrel after MI less effective in diabetes patients
Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal of the American Medical Association.

(HealthDay)—Clopidogrel therapy following a heart attack does less to reduce the risk of death in patients with diabetes than in those without diabetes, according to a study published in the Sept. 5 issue of the Journal of the American Medical Association.

Charlotte Andersson, M.D., Ph.D., from Gentofte Hospital in Hellerup, Denmark, and colleagues analyzed data from the Danish nationwide administrative registries (2002 to 2009) for 58,851 patients hospitalized with incident (MI) who had survived and had not undergone 30 days after discharge.

The researchers found that recurrent MI occurred in 1,790 patients with diabetes (25 percent) and 7,931 patients without diabetes (15 percent); of these, 1,225 with (17 percent) and 5,377 without diabetes (10 percent) died. The unadjusted mortality rates (events/100 person-years) were 13.4 (95 percent confidence interval [CI], 12.8 to 14.0) versus 29.3 (95 percent CI, 28.3 to 30.4) for patients with diabetes treated with clopidogrel versus those not treated. The unadjusted mortality rates were 6.4 (95 percent CI, 6.3 to 6.6) versus 21.3 (95 percent CI, 21.0 to 21.7) for those patients without diabetes treated with clopidogrel versus those not treated. Clopidogrel was associated with significantly less effectiveness for all-cause mortality (hazard ratio, 0.89 [95 percent CI, 0.79 to 1.00] versus 0.75 [95 percent CI, 0.70 to 0.80]) and for (hazard ratio, 0.93 [95 percent CI, 0.81 to 1.06] versus 0.77 [95 percent CI, 0.72 to 0.83]) among patients with diabetes versus those without diabetes.

"Among patients with diabetes compared with patients without diabetes, the use of conventional clopidogrel treatment after MI was associated with lower reduction in the risk of all-cause death and cardiovascular death," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Risk of heart attack in patients

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Risk of heart attack in patients

June 18, 2010

Rheumatoid Arthritis (RA) patients face a two-fold increased risk of suffering a Myocardial Infarction (MI, heart attack) versus the general population, which is comparable to the increased risk of MI seen in diabetes patients, ...

Combo of diabetes, depression increases post-MI mortality

February 27, 2012

(HealthDay) -- Having both diabetes and depression significantly increases the risk of dying in the years following a heart attack, beyond the increased risk from either condition alone, according to a study published in ...

Computer-based screening may reduce teen substance abuse

May 8, 2012

(HealthDay) -- A computer-facilitated screening and provider brief advice (cSBA) system for primary care can increase adolescent receipt of substance use screening across a variety of practice settings, according to a study ...

Depression found to increase risk of death in diabetes

June 1, 2012

(HealthDay) -- For patients with type 2 diabetes, depression is associated with an increased risk of all-cause mortality, regardless of previous cardiovascular disease, according to a study published online May 22 in Diabetes ...

Psoriasis tied to 14 other autoimmune diseases

June 15, 2012

(HealthDay) -- Patients with psoriasis have significantly higher odds for having at least one of 14 other autoimmune diseases, according to a study published online June 4 in the Journal of the American Academy of Dermatology.

Recommended for you

Diets avoiding dry-cooked foods can protect against diabetes

August 24, 2016

Simple changes in how we cook could go a long way towards preventing diabetes, say researchers at the Icahn School of Medicine at Mount Sinai. A new randomized controlled trial, published online July 29 in the journal Diabetologia, ...

New study reveals a novel protein linked to type 2 diabetes

August 16, 2016

Findings from Boston University School of Medicine (BUSM), which appear in eLife, provide a possible explanation as to why most people who are obese develop insulin resistance and type 2 diabetes. A minority of obese individuals, ...

Gene variant explains differences in diabetes drug response

August 9, 2016

The first results from a large international study of patients taking metformin, the world's most commonly used type 2 diabetes drug, reveal genetic differences among patients that may explain why some respond much better ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.